Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. / Ostrowski, Sisse R; Katzenstein, Terese L; Piironen, Timo; Gerstoft, Jan; Pedersen, Bente K; Ullum, Henrik.

I: J A I D S, Bind 35, Nr. 4, 2004, s. 337-42.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ostrowski, SR, Katzenstein, TL, Piironen, T, Gerstoft, J, Pedersen, BK & Ullum, H 2004, 'Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients', J A I D S, bind 35, nr. 4, s. 337-42.

APA

Ostrowski, S. R., Katzenstein, T. L., Piironen, T., Gerstoft, J., Pedersen, B. K., & Ullum, H. (2004). Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J A I D S, 35(4), 337-42.

Vancouver

Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J A I D S. 2004;35(4):337-42.

Author

Ostrowski, Sisse R ; Katzenstein, Terese L ; Piironen, Timo ; Gerstoft, Jan ; Pedersen, Bente K ; Ullum, Henrik. / Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. I: J A I D S. 2004 ; Bind 35, Nr. 4. s. 337-42.

Bibtex

@article{536a4ae1e1424558967dd31bcbd11d2a,

title = "Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients",

abstract = "High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.",

keywords = "Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Drug Administration Schedule, Female, HIV Infections, HIV-1, Humans, Male, Receptors, Cell Surface, Receptors, Tumor Necrosis Factor, Type II, Receptors, Urokinase Plasminogen Activator, Viral Load",

author = "Ostrowski, {Sisse R} and Katzenstein, {Terese L} and Timo Piironen and Jan Gerstoft and Pedersen, {Bente K} and Henrik Ullum",

year = "2004",

language = "English",

volume = "35",

pages = "337--42",

journal = "J A I D S",

issn = "1525-4135",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

RIS

TY - JOUR

T1 - Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients

AU - Ostrowski, Sisse R

AU - Katzenstein, Terese L

AU - Piironen, Timo

AU - Gerstoft, Jan

AU - Pedersen, Bente K

AU - Ullum, Henrik

PY - 2004

Y1 - 2004

N2 - High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.

AB - High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.

KW - Adult

KW - Antiretroviral Therapy, Highly Active

KW - CD4 Lymphocyte Count

KW - Cohort Studies

KW - Drug Administration Schedule

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Male

KW - Receptors, Cell Surface

KW - Receptors, Tumor Necrosis Factor, Type II

KW - Receptors, Urokinase Plasminogen Activator

KW - Viral Load

M3 - Journal article

C2 - 15097149

VL - 35

SP - 337

EP - 342

JO - J A I D S

JF - J A I D S

SN - 1525-4135

IS - 4

ER -

ID: 36144393